Multinational pharmaceutical companies' different performance in Chinese market in 2016q3: four reasons

Source: China's cube data official account 2016-12-6 the multinational pharmaceutical enterprises in the third quarter of this year showed relatively stable performance in China, and remained at a low digit growth rate However, the gap between the "proud" and "frustrated" people in the Chinese market is becoming more and more obvious On the "winner" side, Pfizer is far ahead with a growth rate of 16%, followed by Novo Nordisk and AstraZeneca Driven by specialty products, the growth rate is more than 10% AstraZeneca is mainly respiratory products, Novo Nordisk is mainly insulin products Data source of sales trend of some multinational pharmaceutical companies in 2016q3: informa "losers" where Sanofi, Novartis, MSD and Lilly fell into a growth stagnation or even negative growth dilemma in the third quarter, of which Lilly dropped the most by - 7% (Lilly's revenue is calculated by global sales minus sales in the United States, Japan, Europe and Canada) Sanofi and Novartis fell 1.5% and 3% respectively in China in the third quarter Sanofi's pharmaceutical business grew 13.6% in the third quarter, but the vaccine business fell more (- 15%), resulting in poor overall performance GSK, whose overall performance growth has been stagnant for a long time due to the "crisis event", has finally kept a clear view Before the first reform of the third quarter, GSK's sales have increased by 24% However, the 24% growth rate does not represent the overall recovery of all product lines of GSK China at present GSK's official explanation for this is that "wholesalers should prepare goods ahead of the system upgrade" If this factor is eliminated, sales will increase by 4% This is related to the sharp price reduction of the company's hepatitis B product Werder after the national price negotiation To sum up, in the third quarter, the performance of multinational companies in China was not the same Some achieved double-digit growth, some stagnated, and even showed a downward trend The growth may be related to the following factors: see the link for details: http://mp.weixin.qq.com/s?__biz=MzA4MDA4MTIzMg==&mid=2653045629&idx=1&sn=52918335b88499dc1594f505e1740d7f&chksm=847f5b42b308d254e38cc66597ef02576dd39729d20ebe1daaaf6ba878d83a72c36c626aaf1b&mpshare=1&scene=23&srcid=1206afYzRRLbKqHaxutCzSHR#rd